Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Credit Derivatives [Line Items]
Amount Of Revenue For Contingent Consideration	$ 15.0
Contingent Consideration Classified as Equity
Credit Derivatives [Line Items]
Revenue volatility	30.00%	25.00%
Average of probability of commercialization	80.00%	81.00%
Sales beta	0.50	0.60
Credit rating	B	B
Equity risk premium	6.00%	6.00%
Minimum | Contingent Consideration Classified as Equity
Credit Derivatives [Line Items]
Range of annual revenue subject to revenue sharing	$ 20.2	$ 17.2
Maximum | Contingent Consideration Classified as Equity
Credit Derivatives [Line Items]
Range of annual revenue subject to revenue sharing	$ 21.8	$ 17.3